5 Best Oil Service Stocks To Watch For 2015

5 Best Oil Service Stocks To Watch For 2015: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t h e treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Mass! achusetts.

Advisors' Opinion:

• [By Philip Springer]

  Just last week, the major US stock averages hit all-time highs, led by large-cap stocks, including some that had been lagging for many years. But it’s been a different story in March-April for stocks that had the biggest gains of 2013 and early this year.
  
  This week brought more bad news for the stock market’s two most overvalued sectors, biotechnology and information technology. Worse, when the paddy wagon came, as usual it took the good stocks with the bad, to rephrase an old Wall St aphorism in politically correct terms.
  
  Yesterday, the technology-heavy Nasdaq Composite Index tumbled 3.1 percent, its biggest one-day drop in nearly 2陆 years. This dragged the broader market sharply lower, as investors resumed selling biotechnology stocks in general and many technology stocks. As of April 10, the Nasdaq Composite was 7 percent off its 14-year high, which was reached last month. Yet the S&P 500 and Dow Jones Industrial Average remain not far from their all-time record peaks, down 3 percent and 2.5 percent respectively.
  
  There are many reasons for the decline of both the junk and the good growth stocks. First, the broad market has been long overdue for a 10 percent correction, which still hasn’t occurred.
  
  Second, the high fliers were much more overdue for a reality check. These particularly include extremely overvalued companies in social media, the “cloud,” 3d printing, biotechnology and more.
  
  Third, the new-issues market, which naturally has consisted primarily of info tech and biotech issues, created too much new supply that inevitably dampened investor demand for the more established companies in those sectors.
  
  The increased importance of trading exchange-traded funds, as both a way to invest and to hedge against market declines, inevitably adds to the downward pressure in this situation. Reason: Shares of all of their components are sold, ! regardles! s of each stoc k’s relative me

• [By Jon C. Ogg]

  Biogen Idec Inc. (NASDAQ: BIIB) was reiterated as Outperform, but the target price was raised to $290 from $255 (versus a $244.92 close) based mostly on higher Tecfidera and Hemophilia franchise peak sales estimates, at Credit Suisse.

source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/5-best-oil-service-stocks-to-watch-for-2015.html